The National Institutes of Health cut millions here in research grants. 'There isn't a thoughtful logic,' doctor says. 'There ...

GSK to buy Boston Pharma’s efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD: London, UK Thursday, May 15, 2025, ...